Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Non-Current Assets came in at $18.3 billion in Q2 2026, down 11.95% year-over-year from $20.8 billion in Q2 2025, and down 1.34% quarter-over-quarter from $18.5 billion in Q1 2026.
Analysis
Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Non-Current Assets across 18 years of filings, most recently posting $18.3 billion for Q2 2026.
- In Q2 2026, Non-Current Assets fell 11.95% year-over-year to $18.3 billion; the TTM figure through Jun 2026 stood at $77.6 billion (down 6.96% YoY), while the FY2025 annual figure was $20.2 billion, down 2.6% from the prior year.
- Non-Current Assets came in at $18.3 billion for Q2 2026 at Bausch Health Companies, down from $18.5 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $23.3 billion in Q1 2022 to a low of $18.3 billion in Q2 2026.
- Average Non-Current Assets over 5 years is $21.1 billion, with a median of $21.2 billion recorded in 2023.
- Year-over-year, Non-Current Assets grew 1.47% in 2023 and decreased 11.95% in 2026.
- Over 5 years, Non-Current Assets stood at $21.4 billion in 2022, then rose by 1.47% to $21.8 billion in 2023, then declined by 4.62% to $20.7 billion in 2024, then retreated by 2.6% to $20.2 billion in 2025, then dropped by 9.58% to $18.3 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $18.3 billion in Q2 2026, $18.5 billion in Q1 2026, and $20.2 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.33 Bn | 38.68 Bn | 2.15 Bn | 26.10 Bn |
| 2 | Viatris | 19.05 Bn | 18.16 Bn | 1.46 Bn | 24.99 Bn |
| 3 | Dr Reddys Laboratories | 9.76 Bn | 9.58 Bn | 396.53 Mn | 2.92 Bn |
| 4 | Amneal Pharmaceuticals | 5.38 Bn | 5.25 Bn | 334.51 Mn | 1.83 Bn |
| 5 | Bausch Health Companies | 2.27 Bn | 436.38 Mn | 2.10 Bn | 18.27 Bn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | 1.04 Bn |
| 7 | Ani Pharmaceuticals | 1.51 Bn | 1.15 Bn | 165.89 Mn | 668.68 Mn |
| 8 | Amphastar Pharmaceuticals | 1.03 Bn | 737.26 Mn | 93.47 Mn | 1.11 Bn |
| 9 | Fennec Pharmaceuticals | 393.12 Mn | 351.87 Mn | 17.15 Mn | 3.25 Mn |
| 10 | RedHill Biopharma | 171.02 Mn | 171.02 Mn | - | 18.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.27 Bn |
| Mar 31, 2026 | 18.52 Bn |
| Dec 31, 2025 | 20.21 Bn |
| Sep 30, 2025 | 20.58 Bn |
| Jun 30, 2025 | 20.75 Bn |
| Mar 31, 2025 | 20.69 Bn |
| Dec 31, 2024 | 20.75 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 21.28 Bn |
| Mar 31, 2024 | 21.52 Bn |
| Dec 31, 2023 | 21.75 Bn |
| Sep 30, 2023 | 22.02 Bn |
| Jun 30, 2023 | 21.04 Bn |
| Mar 31, 2023 | 21.21 Bn |
| Dec 31, 2022 | 21.44 Bn |
| Sep 30, 2022 | 22.29 Bn |
| Jun 30, 2022 | 22.75 Bn |
| Mar 31, 2022 | 23.25 Bn |
| Dec 31, 2021 | 23.60 Bn |
| Sep 30, 2021 | 23.93 Bn |